Immunomedics Inc - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immunomedics Inc - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Immunomedics Inc - Product Pipeline Review - 2016', provides an overview of the Immunomedics Inc's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Immunomedics Inc
- The report provides overview of Immunomedics Inc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Immunomedics Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Immunomedics Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Immunomedics Inc's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Immunomedics Inc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immunomedics Inc's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Immunomedics Inc Snapshot 7
Immunomedics Inc Overview 7
Key Facts 7
Immunomedics Inc - Research and Development Overview 8
Key Therapeutic Areas 8
Immunomedics Inc - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Immunomedics Inc - Pipeline Products Glance 17
Immunomedics Inc - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Immunomedics Inc - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Immunomedics Inc - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Immunomedics Inc - Unknown Stage Pipeline Products 22
Unknown Products/Combination Treatment Modalities 22
Immunomedics Inc - Drug Profiles 23
14-3s - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
15-3s - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
19-3s - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
1R-15-15 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
1R-2b - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
1R-3s - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
1R-E1-E1 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
20-3s - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
202-b - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
C2-3s - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
E1-3s - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
epratuzumab - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Hex-hR1 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
IMMU-110 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
IMMU-114 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
IMMU-140 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
labetuzumab govitecan - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
M1-3s - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
milatuzumab - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Monoclonal Antibody Conjugate to Target CD19 for B-Cell Hematologic Malignancies - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Monoclonal Antibody Conjugate to Target CEACAM6 for Colon Cancer and Breast Cancer - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Monocloncal Antibody to Target CD-19 for Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
sacituzumab - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
TF-12 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
TF-2 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
veltuzumab - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
yttrium Y 90 epratuzumab tetraxetan - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Immunomedics Inc - Pipeline Analysis 75
Immunomedics Inc - Pipeline Products by Target 75
Immunomedics Inc - Pipeline Products by Route of Administration 77
Immunomedics Inc - Pipeline Products by Molecule Type 78
Immunomedics Inc - Pipeline Products by Mechanism of Action 79
Immunomedics Inc - Dormant Projects 82
Immunomedics Inc - Discontinued Pipeline Products 83
Discontinued Pipeline Product Profiles 83
clivatuzumab tetraxetan 83
epratuzumab 83
ImmuRAIT-LL2 83
veltuzumab 83
Immunomedics Inc - Company Statement 85
Immunomedics Inc - Locations And Subsidiaries 87
Head Office 87
Other Locations & Subsidiaries 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables

Immunomedics Inc, Key Facts 7
Immunomedics Inc - Pipeline by Indication, 2016 9
Immunomedics Inc - Pipeline by Stage of Development, 2016 13
Immunomedics Inc - Monotherapy Products in Pipeline, 2016 14
Immunomedics Inc - Partnered Products in Pipeline, 2016 15
Immunomedics Inc - Partnered Products/ Combination Treatment Modalities, 2016 16
Immunomedics Inc - Phase III, 2016 17
Immunomedics Inc - Phase II, 2016 18
Immunomedics Inc - Phase I, 2016 19
Immunomedics Inc - Preclinical, 2016 20
Immunomedics Inc - Discovery, 2016 21
Immunomedics Inc - Unknown, 2016 22
Immunomedics Inc - Pipeline by Target, 2016 76
Immunomedics Inc - Pipeline by Route of Administration, 2016 77
Immunomedics Inc - Pipeline by Molecule Type, 2016 78
Immunomedics Inc - Pipeline Products by Mechanism of Action, 2016 80
Immunomedics Inc - Dormant Developmental Projects,2016 82
Immunomedics Inc - Discontinued Pipeline Products, 2016 83
Immunomedics Inc, Other Locations 87
Immunomedics Inc, Subsidiaries 87